Actuate Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ACTU Nasdaq 2834 actuatetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Actuate Therapeutics, Inc.

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer - Jan 7th, 2025 1:00 pm
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer - Dec 17th, 2024 1:28 pm
Actuate Therapeutics to be Added to Russell 2000® Index - Nov 26th, 2024 1:00 pm
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma - Nov 12th, 2024 1:00 pm
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - Oct 29th, 2024 10:39 pm
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor - Sep 23rd, 2024 12:00 pm
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research - Sep 16th, 2024 12:00 pm
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas - Sep 11th, 2024 12:00 pm
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma - Sep 9th, 2024 12:00 pm
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Sep 5th, 2024 1:10 pm
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024 - Aug 20th, 2024 1:00 pm
Actuate Therapeutics Announces Closing of Initial Public Offering - Aug 14th, 2024 8:05 pm
Actuate Therapeutics Announces Pricing of Initial Public Offering - Aug 13th, 2024 12:27 am
Actuate Therapeutics Files Registration Statement for Initial Public Offering - May 28th, 2024 11:00 am